221 results about "Uronic acid" patented technology

The invention relates to the field of medicines, foods or health-care products, in particular to big-fruit hawthorn heteropolysaccharide as well as a preparation method and application thereof. The large-fruit hawthorn heteropolysaccharide is prepared from galacturonic acid, glucuronic acid, mannose, xylose, arabinose, glucose, galactose, fucose and rhamnose. The weight-average molecular weight of the big fruit hawthorn heteropolysaccharide is 81.6 kDa to 157.3 kDa. The product has unique structures of complex monosaccharide composition, low molecular weight, appropriate uronic acid content, low esterification degree and the like; compared with CP which is single in structure and high in esterification, the CP is better in oxidation resistance and bile acid binding capacity; compared with hawthorn polysaccharide with low uronic acid content and high molecular weight, the hawthorn polysaccharide has the advantages that the enzyme inhibition activity is obviously enhanced, and the hawthorn polysaccharide has a wide prospect in development of functional food, health care products or medicines for regulating blood sugar / blood fat, resisting oxidation and preventing metabolic syndromes.

The invention belongs to the technical field of gene engineering, and discloses recombinant yarrowia lipolytica as well as a construction method and application thereof. The recombinant yarrowia lipolytica PGA1 is obtained by carrying out heterologous expression on an arabidopsis thaliana inositol oxygenase gene and a pseudomonas syringae uronic acid dehydrogenase gene in the yarrowia lipolytica by utilizing a genetic engineering technical means. The recombinant yarrowia lipolytica PGA10 capable of efficiently synthesizing glucaric acid (GA) is finally obtained by further modifying six genes of related metabolic pathways of the recombinant yarrowia lipolytica PGA1. The GA yield of the PGA10 reaches 2233.24 mg / L and is 66.27 times that of PGA1, and the effect is remarkable. The invention not only constructs a GA synthesis method, but also defines the influence of related genes such as opi1 on GA synthesis, and provides reference for the research of heterologous synthesis of GA by microorganisms.

The invention relates to the technical field of plant polysaccharides, and particularly discloses a red-knees herb polysaccharide and a preparation method and application thereof, the peak top molecular weight of the red-knees herb polysaccharide is 33.9 KDa, the weight-average molecular weight of the red-knees herb polysaccharide is 42.8 KDa, the number-average molecular weight of the red-knees herb polysaccharide is 10.0 KDa, and the red-knees herb polysaccharide is mainly composed of galacturonic acid, galactose, arabinose, rhamnose and glucuronic acid. According to the preparation method of the red-knees herb polysaccharide, by optimizing process parameters and controlling the reasonable solid-liquid ratio, heating temperature and heating time, the dissolution rate of the polysaccharide is increased, the dissolution rate of impurities is reduced, and the yield of the red-knees herb polysaccharide is increased. The red-knees herb polysaccharide is used as a raw material, ethanol is used for alcohol precipitation, polysaccharide components are precipitated, impurities are preliminarily removed, then macroporous resin is used for purification, the recovery rate of polysaccharide and the removal rate of impurities such as pigment and protein are improved by screening optimization and pretreatment of the macroporous resin, and the total sugar content of the purified red-knees herb polysaccharide is 80% or above. Use of toxic chemical reagents is avoided, and the preparation method is safe and efficient.

The invention relates to the field of microbial strains edited by gene recombination and synthetic biology, and provides recombinant escherichia coli for synthesizing D-xylose by using glucose and application. The recombinant escherichia coli comprises the following modifications: exogenous insertion of a gene IRX for coding beta-1, 4-xylosyltransferase; exogenous insertion of a gene UXS encoding a UDP-glucuronic acid decarboxylase; the invention relates to enhanced expression or overexpression of a gene yagH for coding beta xylosidase. Compared with a traditional hemicellulose hydrolysis method for producing D-xylose, the method for synthesizing and preparing D-xylose through whole-cell catalysis of D-glucose by using the recombinant escherichia coli has the advantages of environmental protection, cost advantage and energy saving.

The invention relates to the technical field of biology, in particular to a recombinant strain for producing glucuronic acid and application of the recombinant strain. The invention provides a recombinant strain for producing glucuronic acid, and the recombinant strain does not express uronic acid isomerase and overexpresses inositol oxidase. The technical scheme of the invention has the following advantages: (1) uronic acid isomerase uxaC from escherichia coli K12 is knocked out, so that glucuronic acid accumulation is increased; and (2) successfully integrating the target gene of the inositol oxidase from the mouse into the escherichia coli K12MG1655. And (3) when the engineering strain is used for catalyzing inositol, the content of glucuronic acid in a system after the reaction is finished is 52.50 g / L, and the conversion rate is as high as 97.23%.

The invention relates to an intestinal probiotic genetically engineered bacterium as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. According to the invention, Escherichia coli is used as an expression host, endogenous recessive plasmid pMUT1 gene and pMUT2 gene are knocked out, an exo-algin lyase gene and an open-loop uronic acid monomer dehydrogenase gene are subjected to heterologous expression, and a 2-keto-3-deoxy-gluconate kinase gene and a 2-keto-3-deoxy-6-phosphate-gluconate aldolase gene are subjected to overexpression. According to the invention, an endogenous recessive plasmid pMUT2 of Escherichia coli Nissle 1917 is utilized, metabolic pathways of algin and degradation products thereof are introduced, and a stable passage engineered strain EcNc-pMUT2 '-4 which can be proliferated by utilizing algin and degradation products thereof and is free of antibiotic markers is obtained, and the engineered strain has good intestinal tract probiotic performance.

The invention provides recombinant escherichia coli for synthesizing glucuronic acid by using glucose and a method for producing glucuronic acid by using the recombinant escherichia coli, and belongs to the field of microbial metabolic engineering. The engineering bacterium is obtained by taking escherichia coli as an original strain and knocking out a glucuronic acid isomerase coding gene uxaC, a 6-phosphofructokinase I coding gene pfkA, a 6-phosphofructokinase II coding gene pfkB and a glucose-6-phosphate dehydrogenase coding gene zwf. The engineering bacterium disclosed by the invention has a good application prospect in industrial production of glucuronic acid.

The invention discloses hippophae rhamnoides polysaccharide with the activity of reducing blood sugar and blood fat as well as a preparation method and application thereof. Adding water into the degreased hippophae rhamnoides, adjusting the pH value to be acidic, then heating, stirring and extracting under an ultrasonic condition, and collecting filtrate; and performing post-treatment to obtain the sea-buckthorn polysaccharide. The content of neutral sugar in the sea buckthorn polysaccharide is 25.31%-30.68%, the content of uronic acid in the sea buckthorn polysaccharide is 54.66%-59.79%, and the content of protein in the sea buckthorn polysaccharide is 1.91%-2.14%. According to the method, the sea-buckthorn polysaccharide is extracted by adopting acid assistance-ultrasonic extraction, and the prepared sea-buckthorn polysaccharide has remarkable blood sugar and blood fat reducing activity. When the concentration of the sea-buckthorn polysaccharide is as low as 0.1 mg / mL, the glucose uptake of HepG2-IR cells can still be obviously improved, and the content of total cholesterol and total triglyceride of the HepG2-IR cells can be obviously reduced. The hippophae rhamnoides polysaccharide can be applied to preparation of food or medicine for reducing blood sugar and / or blood fat.

The application discloses a method for inhibiting growth of pseudomonas by using fucoidan and application thereof, and is characterized in that the fucoidan is a degradation product of natural seaweed (sodium alginate), and is a linear oligosaccharide with a polymerization degree of 2-25 and composed of guluronic acid and mannuronic acid, and has the advantages of safety, health and no toxic side effects; in combination with the research of the inventors that the fucoidan can target and inhibit growth of pseudomonas in vitro and in intestinal flora, the fucoidan can meet the demand of practical application, can be used for delaying corruption and deterioration of fresh food caused by pseudomonas, and can be used for inhibiting growth of pseudomonas on the surface or in the body of aquatic products or fresh food, and has good application prospect and safety.

The invention provides an application of a detection reagent of five tryptophan metabolites in preparation of an early diagnosis kit for ER (estrogen receptor) positive breast cancer. The tryptophan metabolites are kynurenine Kyn, indole-3-carboxylic acid glucuronide I3GA, indole-3-acetic acid I3A, indole-3-acetyl-L-alanine IAA-L-Ala and L-tryptophan L-Trp. According to the invention, early accurate diagnosis of ER positive breast cancer is realized, and the technical problems of insufficient efficiency of traditional diagnosis means and lack of'combined application 'in existing metabolite research are solved.

The application discloses a kind of acanthopanax acid polysaccharides with intestinal protection function and its preparation method and application, belong to the field of functional food and biotechnology.The acanthopanax acid polysaccharide is by water extraction alcohol precipitation, after impurity removal, through DEAE-52 anion exchange column elution and collection 0.2 mol / L NaCl elution peak, and the uniform component obtained by Sephadex G-100 gel column chromatography purification.Its uronic acid content is 30%-40%, weight average relative molecular weight is 50-100kDa, mainly by glucose, galactose, galacturonic acid and arabinose, infrared spectrum has carboxyl characteristic absorption peak at 1736 cm-1 and 1615 cm-1.Experiments prove that the acanthopanax acid polysaccharide has antioxidant activity and hypoglycemic activity.The acid polysaccharide has protective effect on LPS-induced Caco-2 cell damage, can effectively reduce the secretion of pro-inflammatory factors TNF-α, IL-1β, IL-6, and improve the level of anti-inflammatory factor IL-10.The acanthopanax acid polysaccharide can be prepared into oral liquid, tablet candy, solid beverage and other functional food forms.

To provide formulations of protein molecules comprising iduronate 2-sulfatase.SOLUTION: Certain embodiments provide a pharmaceutical composition comprising a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide, a buffer, an isotonicity agent, a surfactant, and a stabilizer, wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, and further provide methods of use thereof. In certain embodiments, the buffer is selected from the group consisting of phosphate buffer, acetate buffer, arginine buffer, and histidine buffer. In certain embodiments, the phosphate buffer is a sodium phosphate buffer or a potassium phosphate buffer.SELECTED DRAWING: None

Provided is a composition for inhibiting the proliferation of bacteria belonging to the genus Collinsella, the composition containing at least one selected from sugar acid-containing oligosaccharides and salts thereof. The sugar acid is preferably selected from aldonic acid, uronic acid, and aldaric acid.

The invention discloses application of GUX1 protein and related biological materials thereof in regulation and control of xylan glucuronic acid modification. Through overexpression of GUX1 in rice and tobacco, the invention finds that the short interval substitution of xylan glucuronic acid in an acceptor material is specifically increased. According to the invention, the function of short-interval glucuronic acid addition of GUX1 mediated xylan is found for the first time, and the GUX1 gene can be used for regulating a glucuronic acid modification mode of plant xylan and producing a corresponding xylan structure product, and is an important and valuable gene for cell wall structure and function modification.

This invention discloses the application of Uncaria rhynchophylla neutral polysaccharide URP-W in the preparation of anti-glioma drugs, belonging to the field of anti-tumor technology of medicinal plant polysaccharides. The invention obtains a crude polysaccharide extract from Uncaria rhynchophylla through hot water extraction and ethanol precipitation, followed by purification using a DEAE cellulose column and G200 dextran gel to obtain Uncaria rhynchophylla neutral polysaccharide URP-W. The monosaccharide composition of URP-W includes arabinose, rhamnose, galactose, glucose, xylose, mannose, galacturonic acid, and mannuronic acid in a molar ratio of 17.99:6.32:21.71:27.17:2.56:7.57:16.20:0.49. Experiments have shown that URP-W can inhibit the proliferation of gliomas and induce apoptosis, exhibiting significant anti-tumor activity against glioma cells, providing a new drug raw material and treatment method for the clinical treatment of gliomas.

The invention belongs to the technical field of biological medicine, and particularly relates to wheat bran araboxylan and application thereof. The invention provides wheat bran AX with specific molecular weight and monosaccharide composition. The wheat bran AX comprises the following monosaccharides: 0.20%-0.22% of glucuronic acid, 0.58%-0.62% of galacturonic acid, 0.21%-0.23% of rhamnose, 0.6%-0.7% of glucose, 1.4%-1.5% of galactose, 18%-19.2% of xylose and 21%-23% of arabinose. Compared with commercially available wheat bran AX, inulin, fructo-oligosaccharide and other common dietary fibers, the self-made wheat bran AX has higher diversity of microbial communities in the fermentation process, has a better intestinal flora regulating effect, further has a good relieving effect on the abnormal glucose and lipid metabolism of the body, and can be used for preventing and treating the abnormal glucose and lipid metabolism of the body. Therefore, the traditional Chinese medicine composition has a good regulation effect on various diseases such as non-alcoholic fatty liver and the like caused by abnormal glucose and lipid metabolism of the organism.

The invention relates to the technical field of pet oral health care, in particular to a compound seaweed source composition for assisting in improving oral health of dogs and cats and application of the compound seaweed source composition. The invention discloses a compound seaweed source composition for assisting in improving oral health of dogs and cats. The compound seaweed source composition comprises sodium alginate and fucoidan, the value of mannuronic acid (M) / guluronic acid (G) in the sodium alginate is 0.96-1.18; the fucoidan is prepared from mannose, glucuronic acid, galactose, xylose and fucose; the weight ratio of the sodium alginate to the fucoidan is 9: 2. The compound seaweed source composition disclosed by the invention has the effects of inhibiting the proliferation of pathogenic bacteria in the oral cavity of a pet, slowing down the rising rate of health indexes of the oral cavity of the pet, inhibiting the generation of volatile organic compounds and ammonia gas in the oral cavity, improving saliva components, slowing down the generation of dental plaque and the like, and can effectively improve the health condition of the oral cavity of the pet.

The application discloses a glucuronolactone and a preparation method thereof, and belongs to the technical field of fine chemical product preparation. The method takes potassium phytate extracted from corn soaking liquid or rice bran acid soaking liquid as raw material, obtains inositol and potassium dihydrogen phosphate after hydrolysis, separates the hydrolysis liquid through chromatography, obtains potassium dihydrogen phosphate by concentrating and crystallizing the salt phase, and the material phase is inositol solution. Enzymatic conversion reaction is carried out by using fermentation to obtain enzyme liquid, glucuronic acid liquid is obtained, glucuronolactone is obtained by concentrating and esterifying, and then the glucuronolactone is obtained by concentrating, refining and crystallizing. In the method, the yield of potassium phytate to inositol is greater than 95%, the molar conversion rate of inositol enzymatic conversion to glucuronic acid is greater than 95%, and the total yield is greater than 89%, which is much higher than the traditional yield, and the content of the obtained glucuronolactone is greater than 99.2%. The glucuronolactone is prepared by enzymatic conversion of the intermediate inositol, the by-product is high-value potassium dihydrogen phosphate, the whole has good economic benefits, and industrial production can be realized.

The invention relates to the cosmetic and non-therapeutic use of a composition consisting essentially of a compound of formula I below: (I) or its enantiomers, isomers or diastereoisomers, or a mixture thereof, or a salt or a solvate thereof, wherein R1 and R2, independently of each other, are a C3-C6 sugar, a uronic acid, or a glucoside, for bleaching or whitening the skin and skin appendages of a healthy individual.

The present invention relates to tablet, capsule and ampoule formulations for oral and / or injectable use, said formulations comprising beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers, or their pharmaceutically acceptable salts, the total amount of [beta]-D-mannuronic acid or [alpha]-L-guluronic acid or mixtures thereof, oligomers thereof, or pharmaceutically acceptable salts thereof is from 10% to 99.999% by weight, based on the total weight of the tablet or capsule formulation, or from 20% to 60% by weight, based on the total weight of the ampoule formulation; the tablet, capsule or ampoule formulation further comprises caffeic acid or a salt thereof, for example in powder form, in an amount preferably from 0.001 wt% to 1 wt%, more preferably from 0.01 wt% to 0.5 wt%, more preferably from 0.05 wt% to 0.3 wt%, based on the total weight of the tablet, capsule or ampoule formulation. Furthermore, the present invention relates to the oral and / or injectable use of tablet, capsule and ampoule formulations, preferably as supplements or medicaments, for use in methods for the treatment of neurodegenerative diseases, inflammatory responses, pain, cancer, aging, diabetes and / or heart diseases, as well as to methods of preparing such formulations.

Provided is a glucuronidase activator containing, as an active ingredient, Levilactobacillus brevis (Levilactobacillusbrevis) strain I-3141 (accession number: CECT 7480).

The invention belongs to the technical field of plant polysaccharide, and particularly discloses caulis spatholobi polysaccharide, a preparation method thereof and application of the caulis spatholobi polysaccharide in preparation of medicines for treating inflammation. Monosaccharide in the caulis spatholobi polysaccharide disclosed by the invention comprises mannose, glucuronic acid, galacturonic acid, glucose and arabinose in a molar ratio of (0.5-0.6): (0.3-0.5): (1-2): (1-2): (0.5-1.5). The caulis spatholobi polysaccharide provided by the invention is a novel uniform-structure polysaccharide which is separated from caulis spatholobi rattan for the first time, has a slightly acidic pH value, definite monosaccharide composition, definite molecular weight and clear glycosidic bond linking mode, has an anti-inflammatory effect, and is expected to be developed into a new anti-inflammatory drug. The preparation process is mild in condition, simple to operate and environment-friendly.

This invention relates to a method for identifying and detecting urinary biomarkers of whole-grain wheat intake. These biomarkers include glycine conjugates of 3,5-dihydroxybenzoic acid, sulfate conjugates of o-aminophenol, sulfate conjugates of 2-acetaminophen, sulfate conjugates of 3,5-dihydroxyphenylvaleric acid, glucuronic acid conjugates of o-aminophenol, or glucuronic acid conjugates of 2-acetaminophen. The invention also relates to a high-throughput screening method for urinary biomarkers of whole-grain wheat intake. A whole-grain wheat dietary intervention experiment was designed, and through comparative analysis of human urinary metabolic profiles, non-targeted metabolomics technology was used to screen for urinary metabolic biomarkers of whole-grain wheat, providing a method for accurately assessing whole-grain wheat intake.

The present invention provides a modified acidic polysaccharide from jujube. Per 100 mg of the modified acidic polysaccharide, the polysaccharide contains: 90.26 mg ± 1.39 mg–94.42 mg ± 1.83 mg total polysaccharides; 21.42 mg ± 1.01 mg–50.72 mg ± 0.62 mg total uronic acid; and 0.65 mg GAE ± 0.05 mg GAE–1.21 mg GAE ± 0.03 mg GAE total bound phenols (gallic acid equivalent). The present invention also provides a preparation method and uses of the modified acidic polysaccharide from jujube. The invention modifies jujube acidic polysaccharides through low-temperature alkaline deesterification technology, directional enzyme cutting technology and controllable partial acid hydrolysis technology, and compares the in vivo and in vitro immunoregulatory activities of the jujube acidic polysaccharides before and after modification. The immunoregulatory activity of the modified jujube acidic polysaccharides obtained by the modification is significantly enhanced, especially the modified jujube acidic polysaccharides with the arabinan side chains removed and the galactan side chains reduced, which have better immunoregulatory activity.

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

The invention belongs to the technical field of traditional Chinese medicine, and relates to polygonum cuspidatum homogeneous polysaccharide and a preparation method and application thereof.The polygonum cuspidatum homogeneous polysaccharide is mainly composed of galacturonic acid, rhamnose, galactose, glucuronic acid, glucose, mannose, xylose and glucuronide amine according to the molar ratio of 41.967: 24.624: 17.951: 5.427: 4.59: 3.501: 1.236: 0.358, and the weight-average molecular weight of the polygonum cuspidatum homogeneous polysaccharide is 26.57 kDa. The polygonum cuspidatum homogeneous polysaccharide is fixed in component, high in yield, good in hypoglycemic effect and good in safety, and a basis is provided for development of innovative hypoglycemic drugs.

The invention relates to the technical field of cosmetics, in particular to acer truncatum moisturizing pre-makeup cream and a preparation method thereof. The acer truncatum moisturizing makeup pre-cream is prepared from the following components in parts by weight: acer truncatum seed oil, cosmetic-grade purified water, cetyl PEG / PPG-10 / 1 polydimethylsiloxane, polydimethylsiloxane, isononyl isononanoate, synthetic wax, microcrystalline wax, glycerol, 1, 2, 4-trimethyl-1, 3-pentanediol monoisobutyrate, propylene glycol monobutyl ether, propylene glycol monobutyl ether, propylene glycol monobutyl ether, propylene glycol monobutyl ether, propylene glycol monobutyl ether, propylene glycol the mannuronic acid tetrasaccharide micro-capsule is coated with 1, 3-propylene glycol / caprylyl glycol / ethylhexylglycerin, butanediol, sodium chloride, a sodium hyaluronate cross-linked polymer and temperature-sensitive polyglycerol-10 stearate. The acer truncatum seed oil containing 6% of nervonic acid serves as core lipid, temperature-sensitive type microencapsulated mannuronic acid tetrasaccharide and response type composite microcapsules are compounded, a'instant moisturizing-delayed moisturizing-barrier repairing 'triple synergistic system is constructed, the defects of a traditional technology are overcome, and the requirements of consumers for long-acting, efficient and mild pre-makeup care are met.

The invention belongs to the technical field of medicines, and particularly relates to safflower polysaccharide for lung targeting as well as a preparation method and application thereof. The safflower polysaccharide comprises the following monosaccharides in percentage by mole: 0.75% of L-fucose, 36.04% of arabinose, 25.03% of rhamnose, 17.85% of galactose, 4.26% of glucose, 1.33% of xylose, 0.61% of mannose, 12.07% of galacturonic acid and 2.06% of glucuronic acid, and the total percentage is 100%. The molecular weight of the safflower polysaccharide is 16.27 kDa. The safflower polysaccharide disclosed by the invention can be absorbed into blood within 24 hours and almost completely metabolized, and can be used for preparing lung targeting products.

The invention discloses a preparation method and application of a quercetin derivative grafted with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione with a blood sugar reducing function. According to the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound disclosed by the invention, the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is prepared by linking quercetin-3-O-glucuronide with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione, the structural formula of the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is shown as a formula (I), and the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound prepared by the invention has the function of reducing blood sugar and can be used for preparing medicines for treating diabetes mellitus.

The invention discloses a keloid treatment gel material capable of reducing lactic acid generation, and belongs to the technical field of keloid treatment. The material is prepared by the following steps: firstly, carrying out esterification on 9-oxabicyclo [3.3. 1] nonane-2, 6-diol and S-allyl-L-cysteine to obtain an intermediate A, and then carrying out Schiff base reaction on the intermediate A and 5-methoxy heliotropin to obtain an intermediate B containing double bonds; then, copolymerizing with methylacryloylated chitosan and polyethylene glycol diacrylate under photo-initiation to form a cross-linked network structure; finally, active ingredients such as quercetin-3-O-glucuronide and luteolin-3 '-glucuronide are included, and auxiliary materials such as a humectant and a preservative are added, so that the composition is prepared. The gel has a slow release function, can effectively inhibit glycolysis, reduce lactic acid generation, scavenge free radicals and regulate inflammation and fibrosis microenvironment, has good biocompatibility and oxidation response drug release characteristics, and is suitable for prevention and treatment of keloids.